Compugen (CGEN) Capital Expenditures (2009 - 2010)
Compugen (CGEN) posted quarterly Capital Expenditures of $88000.0 for Q4 2010, up 23.94% year-over-year from $71000.0 in Q4 2009, and up 344.44% on a QoQ basis from -$36000.0 in Q3 2010.
Powered by 
Analysis
Compugen (CGEN) Capital Expenditures (2009 - 2010) Analysis & Trends
Compugen has reported Capital Expenditures for 2 years, with the latest figure at $88000.0 in Q4 2010.
- Capital Expenditures for Q4 2010 came in at $88000.0, up 23.94% year-over-year; the trailing twelve-month figure through Dec 2010 was $112000.0 (changed N/A YoY), and the FY2025 annual result was $306000.0, up 159.32% from the prior year.
- Capital Expenditures advanced to $88000.0 in Q4 2010, from -$36000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $88000.0 in Q4 2010 and troughed at -$36000.0 in Q3 2010.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Compugen | 242.44 Mn | 156.82 Mn | -92,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2010 | -4,000.00 |
| Sep 30, 2010 | -36,000.00 |
| Dec 31, 2009 | -25,000.00 |
| Sep 30, 2009 | -11,000.00 |